PMID- 27654088
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220310
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 26
IP  - 8
DP  - 2016 Oct
TI  - Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased 
      Disease-Free and Disease-Specific Survival in Patients With Cervical 
      Adenocarcinoma.
PG  - 1503-1509
AB  - OBJECTIVES: Human leukocyte antigen (HLA) class II antigens are expressed on 
      antigen-presenting cells, that is, macrophages, dendritic cells, and B 
      lymphocytes. Under the influence of IFN-gamma, HLA class II molecules can also be 
      expressed on T lymphocytes, epithelial and endothelial cells. In addition, HLA 
      class II antigens can be expressed in a variety of malignancies; however, the 
      link with prognosis and ultimately patient survival is controversial. METHODS: 
      The pattern of HLA-DRA expression in cervical carcinoma was studied using 
      immunohistochemistry. In total, 124 cervical carcinomas were examined, of which 
      60 (48.4%) were squamous cell carcinomas and 64 (51.6%) were adenocarcinomas. 
      RESULTS: In squamous cell carcinoma, HLA-DRA was expressed in 41 (68.3%) of 60 
      tumors, whereas in adenocarcinoma, HLA-DRA was expressed in 60 (93.8%) of 64 
      tumors (P < 0.001). In adenocarcinoma, HLA-DRA expression was associated with an 
      increased disease-free survival (211.0 +/- 13.0 vs 53.3 +/- 30.5 months; P = 0.004) 
      and disease-specific survival (226.45 +/- 11.5 vs 75.8 +/- 27.6 months; P = 0.002). 
      CONCLUSIONS: Upregulation of HLA-DRA is significantly related to an increased 
      disease-free and disease-specific survival in cervical adenocarcinoma. These data 
      warrant further analysis of the functional role of HLA-DRA in these tumors.
FAU - Samuels, Sanne
AU  - Samuels S
AD  - *Department of Gynaecology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 
      Center Gynaecology Oncology Amsterdam (CGOA), Department of Gynaecology, 
      Netherlands Cancer Institute, Amsterdam, daggerDepartment of Gynaecology and 
      Obstetrics, Leiden University Medical Center, Leiden, the Netherlands, 
      double daggerDepartment of Pathology, Leiden University Medical Centre, Leiden, the 
      Netherlands; and  section signCenter Gynaecological Oncology Amsterdam (CGOA), Department of 
      Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, the 
      Netherlands.
FAU - Spaans, Vivian M
AU  - Spaans VM
FAU - Osse, Michelle
AU  - Osse M
FAU - Peters, Lex A W
AU  - Peters LA
FAU - Kenter, Gemma G
AU  - Kenter GG
FAU - Fleuren, Gertjan J
AU  - Fleuren GJ
FAU - Jordanova, Ekaterina S
AU  - Jordanova ES
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
EDAT- 2016/09/23 06:00
MHDA- 2016/09/23 06:01
CRDT- 2016/09/23 06:00
PHST- 2016/09/23 06:00 [entrez]
PHST- 2016/09/23 06:00 [pubmed]
PHST- 2016/09/23 06:01 [medline]
AID - 00009577-201610000-00022 [pii]
AID - 10.1097/IGC.0000000000000783 [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2016 Oct;26(8):1503-1509. doi: 
      10.1097/IGC.0000000000000783.